Your shopping cart is empty

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > BMS, AZ Hope to Fill Future Medicine Cabinets With Amylin Diabetes Drugs

Drug Industry Daily

July 3, 2012 | Vol. 11 No. 130

BMS, AZ Hope to Fill Future Medicine Cabinets With Amylin Diabetes Drugs

AstraZeneca (AZ) and Bristol-Myers Squibb (BMS) are restocking the development pipelines with diabetes drugs from Amylin Pharmaceuticals after the two pharma giants joined forces to buy the diabetes specialist.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Actavis Buys Warner Chilcott In $8.5B All Stock Purchase Mylan Doubles Down on Injectables With $1.6 Billion Buy of India’s Agila Taro, Sun Terminate Merger Plans After Years of Disagreement Taro, Sun Terminate Merger Plans

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.